KR20230022880A - 라벡시모드의 결정성 형태를 포함하는 경구 제형 - Google Patents

라벡시모드의 결정성 형태를 포함하는 경구 제형 Download PDF

Info

Publication number
KR20230022880A
KR20230022880A KR1020227045211A KR20227045211A KR20230022880A KR 20230022880 A KR20230022880 A KR 20230022880A KR 1020227045211 A KR1020227045211 A KR 1020227045211A KR 20227045211 A KR20227045211 A KR 20227045211A KR 20230022880 A KR20230022880 A KR 20230022880A
Authority
KR
South Korea
Prior art keywords
rabeximod
solid oral
oral composition
composition according
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045211A
Other languages
English (en)
Korean (ko)
Inventor
울프 비요르크룬드
Original Assignee
사익손 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사익손 아베 filed Critical 사익손 아베
Publication of KR20230022880A publication Critical patent/KR20230022880A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020227045211A 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 포함하는 경구 제형 Pending KR20230022880A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20179279.3 2020-06-10
EP20179279 2020-06-10
EP20179277.7 2020-06-10
EP20179239 2020-06-10
EP20179277 2020-06-10
EP20179239.7 2020-06-10
EP20180706 2020-06-18
EP20180706.2 2020-06-18
PCT/EP2021/065705 WO2021250204A1 (en) 2020-06-10 2021-06-10 Oral formulation comprising a crystalline form of rabeximod

Publications (1)

Publication Number Publication Date
KR20230022880A true KR20230022880A (ko) 2023-02-16

Family

ID=76305939

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227045211A Pending KR20230022880A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 포함하는 경구 제형
KR1020227045212A Pending KR20230022881A (ko) 2020-06-10 2021-06-10 류마티스 관절염의 치료에서의 라벡시모드
KR1020227045213A Pending KR20230022882A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 제조하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227045212A Pending KR20230022881A (ko) 2020-06-10 2021-06-10 류마티스 관절염의 치료에서의 라벡시모드
KR1020227045213A Pending KR20230022882A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 제조하는 방법

Country Status (8)

Country Link
US (3) US12594274B2 (https=)
EP (3) EP4164650A1 (https=)
JP (3) JP2023529001A (https=)
KR (3) KR20230022880A (https=)
CN (4) CN115768431A (https=)
AU (3) AU2021290174A1 (https=)
CA (3) CA3181629A1 (https=)
WO (3) WO2021250197A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
US11643415B1 (en) 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
JPH08165278A (ja) 1994-12-14 1996-06-25 Kawaken Fine Chem Co Ltd １−置換トリプタミン化合物の製造方法
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
US6333327B2 (en) 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
SE516067C2 (sv) 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
SE527639C2 (sv) 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner
WO2008066151A1 (fr) * 2006-11-30 2008-06-05 Tokyo Institute Of Technology Nouveau dérivé curcumine
CN102115457B (zh) 2011-03-05 2012-11-21 太原理工大学 一种n-乙基咔唑的制备方法
US20150079111A1 (en) * 2012-06-05 2015-03-19 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
EA201500942A1 (ru) 2013-03-15 2016-03-31 Виронова Херпес Аб ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
CN105061432B (zh) * 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
TWI842978B (zh) * 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
KR20230022880A (ko) 2020-06-10 2023-02-16 사익손 아베 라벡시모드의 결정성 형태를 포함하는 경구 제형
EP4164649A1 (en) 2020-06-10 2023-04-19 Cyxone AB New use of rabeximod
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Also Published As

Publication number Publication date
CA3181637A1 (en) 2021-12-16
KR20230022882A (ko) 2023-02-16
US12594274B2 (en) 2026-04-07
JP2023529877A (ja) 2023-07-12
WO2021250199A1 (en) 2021-12-16
CA3181646A1 (en) 2021-12-16
WO2021250204A1 (en) 2021-12-16
JP2023533662A (ja) 2023-08-04
AU2021289006A1 (en) 2023-02-09
EP4165043A1 (en) 2023-04-19
EP4164616A1 (en) 2023-04-19
CN115698010A (zh) 2023-02-03
CN115768431A (zh) 2023-03-07
US20220133717A1 (en) 2022-05-05
WO2021250197A1 (en) 2021-12-16
US20230227455A1 (en) 2023-07-20
EP4164650A1 (en) 2023-04-19
CA3181629A1 (en) 2021-12-16
AU2021290174A1 (en) 2023-02-09
JP2023529001A (ja) 2023-07-06
US20230227456A1 (en) 2023-07-20
CN115697308A (zh) 2023-02-03
CN120383602A (zh) 2025-07-29
AU2021290173A1 (en) 2023-02-09
KR20230022881A (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
KR101830147B1 (ko) 벤다무스틴의 경구 투약 형태 및 그것의 치료 용도
WO2013044356A1 (en) Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
CN104470519A (zh) 不含碱化剂的拉喹莫德调配物
KR20230022880A (ko) 라벡시모드의 결정성 형태를 포함하는 경구 제형
EP2514422B1 (en) Elution stabilized teneligliptin preparation
EP4221704B1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
HUP0004363A2 (hu) Miltefosint tartalmazó orális szilárd gyógyszerkészítmények leishmaniasis kezelésére
CN106560179B (zh) 盐酸卡利拉嗪药物组合物及其制备方法
EP2709600A1 (en) Pharmaceutical composition comprising fexofenadine
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
EP2915526B1 (en) Pharmaceutical compositions comprising anagrelide
EP4514792A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
MX2015000467A (es) Composicion farmaceutica que tiene fluidez mejorada, un agente medicinal y metodo para producir y usar la misma.
WO1996004917A1 (en) Remedy for myotonic dystrophy
US20260069569A1 (en) Ebselen containing oral dosage forms
WO2024255858A1 (zh) 一种肽酰胺类化合物的口服药物组合物及其制备方法
AU2024311302A1 (en) Oral formulations comprising avatrombopag and related uses
CN115103668A (zh) 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺的药物组合物
UA146734U (uk) Готовий лікарський засіб для симптоматичного лікування болю
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
AU2012260992A1 (en) Pharmaceutical composition comprising fexofenadine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902